India, Nov. 17 -- Edesa Biotech, Inc. (EDSA) announced that the European Commission (EC) has granted orphan designation to paridiprubart for the treatment of acute respiratory distress syndrome.

Acute respiratory distress syndrome (ARDS) is associated with high mortality rates, and there are currently no approved drug treatments for the condition.

The designation follows a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products and provides regulatory incentives that may help support the drug's development and commercialization in Europe.

Among the benefits of orphan designation is the potential for up to 10 years of market exclusivity in the European Union following approval, as well as reduc...